Skip to content

A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain

CompletedPhase 2NCT02436824
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

The objectives of this study are to examine the safety, tolerability, and efficacy of repeated topical administration of AB001 topical patches for the treatment of chronic low back pain.

Study details

Official title
A Phase II, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Determine the Safety and Efficacy of a Topical Patch (AB001) Following Daily Administration for 2 Weeks in Patients With Chronic Low Back Pain
Interventions
  • Drug: AB001 patch
  • Other: Placebo patch
Sponsor
Frontier Biotechnologies Inc.
Start date
2015-04
Primary completion
2015-07
Sex
All
Age range
from 18 Years to 75 Years
Results posted
No results posted in this snapshot
Countries
United States
Total sites listed
9

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Are generally healthy males or non-pregnant females, 18 to 75 years of age. 2. Have a body mass index (BMI) ≤35. 3. Have chronic low back pain for at least 3 months. 4. Have low back pain that is located inferior to the twelfth thoracic vertebra (T-12). 5. Back pain classified, using the Quebec Task Force system, as either Class 1 or Class 2. 6. Currently require use of analgesics for lower back pain (required at least 3 days per week for at least the last 4 weeks). 7. Have a score of 30 mm or greater on the visual analog scale (VAS) and a score of 2, 3, or 4 on the Subject Global Assessment (SGA) of Back Pain Scale at Screening. 8. Are willing to discontinue current analgesics for the 3 to 15 day washout period. 9. Have an increase of at least 10 mm or more from the score at Screening and an absolute score of 50 mm or more on the VAS (ie, VAS ≥ 50 mm) and a score of 3 or 4 on the SGA of Back Pain Scale at Baseline. 10. If female, are: 1).Of non-childbearing potential or have a confirmed clinical history of sterility or, 2).Of childbearing potential, must be willing to use effective contraception at trial entry and until completion. 11. Are willing to provide written informed consent. Exclusion Criteria: 1. Have chronic lower back pain (CLBP) due to any of the following pathologies: infection, neoplasia, metabolic or structural disturbance of spine, lumbar radiculopathy, osteoporosis, hip dysplasia, inflammatory arthritis, ankylosing spondylitis, Paget's disease, cauda equine syndrome, gout, pseuodgout, fibromyalgia, post-surgical pain. 2. Have low back pain caused by major trauma. 3. Have excess hair, tattoo(s), or other dermatologic conditions in the patch application area that might interfere with efficacy evaluation. 4. Have had surgery for low back pain within the previous 6 months. 5. Have had clinical depression within 2 years or are currently undergoing treatment for depression; 6. Have a hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs, including aspirin) or hypersensitivity to acetaminophen. 7. Have used opioids within 72 hours prior to the Baseline / Day 1 visit or during the course of the study. 8. Have used oral or injected corticosteroids chronically or intermittently within the past 60 days (oral), or 90 days (injected). 9. Are a current drug or alcohol abuser. 10. Are pregnant, plan to become pregnant during the study, or are breastfeeding. 11. Have a pending workman's compensation claim, litigation, …

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02436824